诱导依赖于STING的DNA损伤途径可增强骨髓瘤免疫疗法的有效性
Bin Luo1, Qing Lu2, Qiang Wang1
1Department of Orthopaedics, Changshu Hospital Affiliated to Nanjing University of Chinese Medicine, Changshu 215500, China.
Iranian journal of basic medical sciences
|September 2, 2025
概括
通过破坏癌症DNA和激活免疫反应,库库比他素B (CuB) 显示出对骨髓瘤的承诺. 将CuB与抗PD- L1疗法结合,进一步增强了其抑制瘤的作用.
科学领域:
- 癌症学
- 免疫学
- 自然产品化学
背景情况:
- 骨肉瘤 (OS) 是一种具有有限治疗选择的侵袭性骨癌.
- 库库比他素B (CuB) 是一种天然化合物,具有抗瘤特性,但其在OS中的作用尚未完全理解.
研究的目的:
- 研究皮素B (CuB) 在骨肉瘤 (OS) 中的抗瘤作用.
- 探索CuB在OS中的作用的分子机制.
- 评估CuB与抗编程死亡配体1 (PD- L1) 治疗的协同作用.
主要方法:
- 在用CuB治疗的OS细胞上进行了细胞活力,增殖,细胞亡和细胞周期测试.
- 分析了DNA损伤,STING通路的激活和免疫细胞的透.
- 在体内使用异种移植模型来评估瘤生长和治疗疗效.
主要成果:
- CuB 抑制了 OS 细胞的增殖,诱导了细胞亡,并导致 G2/ M 细胞循环停止.
- 在体内激活了STING通路并诱导DNA损伤,减少瘤生长和转移.
- CuB 增强了 CD8+ 和 CD4+ T 细胞的透,同时减少了调节性 T 细胞和骨髓衍生抑制细胞.
- 与抗PD- L1的联合治疗显著抑制了瘤的生长.
结论:
- 通过诱导DNA损伤和激活STING通路,库库比B具有显著的抗骨肉瘤活性.
- 这表明它具有作为免疫治疗剂的潜力.
- CuB与抗PD-L1疗法协同作用,为骨髓瘤治疗提供了一个有前途的联合策略.
相关概念视频
Tumor Immunotherapy
659
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
659
Induced Pluripotent Stem Cells
4.4K
Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
Somatic...
4.4K
Inhibition of Cdk Activity
4.9K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Drugs that Stabilize Microtubules
2.1K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.1K


